Search
AI-powered search, human-powered content.
scroll to top arrow or icon

{{ subpage.title }}

Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark.

REUTERS/Tom Little

How Ozempic is funding an AI supercomputer

The Danish company Novo Nordisk has gotten rich off of the success of Ozempic and Wegovy — two variants of the revolutionary drug called semaglutide that’s used for diabetes and weight loss respectively under different brand names. Since 2020, the company’s stock price has quadrupled. One of the biggest beneficiaries has been the Novo Nordisk Foundation, the pharmaceutical giant’s charitable arm and its largest shareholder.

Read moreShow less

Subscribe to our free newsletter, GZERO Daily

Latest